MONTREAL, Jan. 14, 2025 /CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that eligible patients in Ontario now have access to Pluvicto™ (lutetium (177 Lu ...

MONTREAL, Jan. 14, 2025 /CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that eligible patients in Ontario now have access to Pluvicto™ (lutetium (177Lu ...

This year, the Outpatient Theranostics Center at UCLA Health celebrates its first anniversary of many. UCLA Health is celebrating one year of treating patients with advanced prostate, thyroid and ...

MONTREAL, Jan. 14, 2025 /CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that eligible patients in Ontario now have access to Pluvicto™ (lutetium (177 Lu) vipivotide ...

Four years later, Novartis secured FDA approval for prostate cancer treatment Pluvicto, which has quickly become the most successful radioligand therapy ever, generating sales of $1.04 billion in ...

Health Canada approved Pluvicto in August 2022, but patients have been waiting since then for provincial health plans to announce coverage. Health Minister Sylvia Jones says Ontario is the first ...

LONDON — The Ontario government is connecting more people to care by being the first Canadian jurisdiction to publicly fund and administer PLUVICTO TM a new treatment for advanced-stage prostate ...